Literature DB >> 21095574

Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.

Lisa M Wodicka1, Pietro Ciceri, Mindy I Davis, Jeremy P Hunt, Mark Floyd, Sara Salerno, Xuequn H Hua, Julia M Ford, Robert C Armstrong, Patrick P Zarrinkar, Daniel K Treiber.   

Abstract

Interactions between kinases and small molecule inhibitors can be activation state dependent. A detailed understanding of inhibitor binding therefore requires characterizing interactions across multiple activation states. We have systematically explored the effects of ABL1 activation loop phosphorylation and PDGFR family autoinhibitory juxtamembrane domain docking on inhibitor binding affinity. For a diverse compound set, the affinity patterns correctly classify inhibitors as having type I or type II binding modes, and we show that juxtamembrane domain docking can have dramatic negative effects on inhibitor affinity. The results have allowed us to associate ligand-induced conformational changes observed in cocrystal structures with specific energetic costs. The approach we describe enables investigation of the complex relationship between kinase activation state and compound binding affinity and should facilitate strategic inhibitor design.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21095574     DOI: 10.1016/j.chembiol.2010.09.010

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  42 in total

1.  Comprehensive analysis of kinase inhibitor selectivity.

Authors:  Mindy I Davis; Jeremy P Hunt; Sanna Herrgard; Pietro Ciceri; Lisa M Wodicka; Gabriel Pallares; Michael Hocker; Daniel K Treiber; Patrick P Zarrinkar
Journal:  Nat Biotechnol       Date:  2011-10-30       Impact factor: 54.908

2.  Interrogating the kinome.

Authors:  Chao Zhang; Gaston Habets; Gideon Bollag
Journal:  Nat Biotechnol       Date:  2011-11-08       Impact factor: 54.908

3.  Dual Inhibition of PI3K/Akt and mTOR by the Dietary Antioxidant, Delphinidin, Ameliorates Psoriatic Features In Vitro and in an Imiquimod-Induced Psoriasis-Like Disease in Mice.

Authors:  Jean Christopher Chamcheu; Vaqar M Adhami; Stephane Esnault; Mario Sechi; Imtiaz A Siddiqui; Kenneth A Satyshur; Deeba N Syed; Shah-Jahan M Dodwad; Maria-Ines Chaves-Rodriquez; B Jack Longley; Gary S Wood; Hasan Mukhtar
Journal:  Antioxid Redox Signal       Date:  2016-10-04       Impact factor: 8.401

4.  A Chemical Probe Strategy for Interrogating Inhibitor Selectivity Across the MEK Kinase Family.

Authors:  Kristine K Deibler; Rama K Mishra; Matthew R Clutter; Aleksandar Antanasijevic; Raymond Bergan; Michael Caffrey; Karl A Scheidt
Journal:  ACS Chem Biol       Date:  2017-03-20       Impact factor: 5.100

5.  A novel mode of protein kinase inhibition exploiting hydrophobic motifs of autoinhibited kinases: discovery of ATP-independent inhibitors of fibroblast growth factor receptor.

Authors:  Sudharshan Eathiraj; Rocio Palma; Marscha Hirschi; Erika Volckova; Enkeleda Nakuci; Jennifer Castro; Chang-Rung Chen; Thomas C K Chan; Dennis S France; Mark A Ashwell
Journal:  J Biol Chem       Date:  2011-03-24       Impact factor: 5.157

6.  Can structural features of kinase receptors provide clues on selectivity and inhibition? A molecular modeling study.

Authors:  Sarangan Ravichandran; Brian T Luke; Jack R Collins
Journal:  J Mol Graph Model       Date:  2015-01-12       Impact factor: 2.518

7.  Discovery of AC710, a Globally Selective Inhibitor of Platelet-Derived Growth Factor Receptor-Family Kinases.

Authors:  Gang Liu; Brian T Campbell; Mark W Holladay; Julia M Ford Pulido; Helen Hua; Dana Gitnick; Michael F Gardner; Joyce James; Mike A Breider; Daniel Brigham; Barbara Belli; Robert C Armstrong; Daniel K Treiber
Journal:  ACS Med Chem Lett       Date:  2012-09-24       Impact factor: 4.345

8.  Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.

Authors:  Weiguo Zhang; Chen Gao; Marina Konopleva; Ye Chen; Rodrigo O Jacamo; Gautam Borthakur; Jorge E Cortes; Farhad Ravandi; Abhijit Ramachandran; Michael Andreeff
Journal:  Clin Cancer Res       Date:  2014-03-11       Impact factor: 12.531

9.  Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.

Authors:  Eric I Zimmerman; David C Turner; Jassada Buaboonnam; Shuiying Hu; Shelley Orwick; Michael S Roberts; Laura J Janke; Abhijit Ramachandran; Clinton F Stewart; Hiroto Inaba; Sharyn D Baker
Journal:  Blood       Date:  2013-09-17       Impact factor: 22.113

10.  Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.

Authors:  Sharyn D Baker; Eric I Zimmerman; Yong-Dong Wang; Shelley Orwick; Douglas S Zatechka; Jassada Buaboonnam; Geoffrey A Neale; Scott R Olsen; Eric J Enemark; Sheila Shurtleff; Jeffrey E Rubnitz; Charles G Mullighan; Hiroto Inaba
Journal:  Clin Cancer Res       Date:  2013-08-22       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.